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EDITORIAL
Treatment  of  umbilical  cord  blood  units  with
interleukin-15 improves  hematopoietic  stem  cell
engraftment
El  tratamiento  de  unidades  de  cordón  umbilical  con  interleucina  15  mejora
el injerto  de  células  madre  hematopoyéticas
R. Laza-Briviescaa, A. Saudemonta,b, J.A. Madrigala,b,∗
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tUmbilical  cord  blood  is  increasingly  used  as  a  source  of
hematopoietic  stem  cells  for  transplantation  due  to  less
stringent  Human  Leukocyte  Antigen  (HLA)  matching  require-
ment,  rapid  availability  of  the  graft  and  lower  incidence  and
severity  of  graft  versus  host  disease  observed  post  umbilical
cord  blood  transplantation.1
Umbilical  cord  blood  transplantation  has  many  advan-
tages  but  it  also  has  some  disadvantages  such  as  delayed
immune  reconstitution  and  engraftment,  graft  failure,
higher  incidence  of  infection,  limited  cell  number  and  no
possibility  of  donor  lymphocyte  infusion  (DLI).  Many  stud-
ies  are  focusing  on  overcoming  these  issues  by  increasing
the  cell  dose  of  umbilical  cord  blood  units  for  adult  patients
by  performing  double  umbilical  cord  blood  transplantation
or  ex  vivo  expansion  of  umbilical  cord  blood  hematopoi-
etic  stem  cells,  intra-bone  infusion  of  umbilical  cord  blood,
expanding  speciﬁc  cell  population  such  as  natural  killer
(NK)  cells  or  regulatory  T  cells,  using  cytokines  to  enhance
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hymopoiesis.1
NK  cells  are  innate  immune  lymphocytes  that  recon-
titute  after  umbilical  cord  blood  transplantation  and  key
ffectors  of  the  graft  versus  leukaemia  effect.1 Interleukin
IL)-15  is  a  cytokine  that  induces  NK  cell  maturation,  pro-
iferation,  survival  and  differentiation.2 The  infusion  of  NK
ells  together  with  IL-15  has  been  tested  in  phase  I clin-
cal  trials  for  patients  with  acute  myeloid  leukaemia  or
olid  tumours  showing  that  therapy  to  be  feasible  and  safe
hile  reducing  relapse  rate,  inducing  expansion  of  donor  NK
ells,  and  increasing  engraftment.3,4 However,  even  if  these
esults  are  promising,  further  studies  need  to  be  done  to
onsolidate  a  therapy.  For  example,  NK  cells  were  infused
etween  days  7  and  30  after  haplo  hematopoietic  stem  cells
ransplantation  leading  to  an  improved  anti-tumour  effect
n  vitro  with  no  toxicity,  but  when  NK  cells  should  be  infused
or  this  therapy  to  be  optimal  is  still  unclear.
We  have  recently  shown  that  umbilical  cord  blood  NK
ells  are  better  activated  by  IL-15  than  other  cytokines  such
s  IL-2,  IL-12  or  IL-18.2 In  addition,  we  found  that  IL-15
ctivated  NK  cells  could  facilitate  engraftment  of  umbilical
ord  blood  hematopoietic  stem  cells  while  also  increasing
heir  homing  to  the  bone  marrow  and  clonogenicity.5 Our
esults  suggest  that  the  co-infusion  of  IL-15  activated  autol-
gous  umbilical  cord  blood  NK  cells  together  with  the  graft
ould  double  the  levels  of  engraftment  after  umbilical  cord
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lood  transplantation.  Therefore,  we  are  currently  testing
hether  the  treatment  of  the  umbilical  cord  blood  graft  with
L-15  could  improve  hematopoietic  stem  cells  homing  to  the
one  marrow  and  increase  their  clonogenicity  in  a  similar
anner  as  this  therapy  could  lead  to  improve  neutrophil  and
latelet  engraftment  in  umbilical  cord  blood  transplantation
atients  and  long-term  be  an  alternative  to  the  use  of  double
mbilical  cord  blood  transplantation.
We  are  evaluating  the  possibilities  to  either  treat  a  whole
mbilical  cord  blood  unit  with  IL-15  prior  infusion  to  the
atient  as  well  as  developing  a  NK  cell  therapy  to  improve
ngraftment  by  optimising  the  selection  of  NK  cells  from  20%
f  a  umbilical  cord  blood  unit,  so  the  selected,  IL-15  acti-
ated  NK  cells  could  be  added  to  the  rest  of  the  graft  prior
nfusion.  In  this  context,  we  are  planning  to  test  such  an
pproach  in  a  ﬁrst  instance  in  the  context  of  double  umbili-
al  cord  blood  transplantation  infusing  one  non-manipulated
nit  and  one  treated  with  IL-15  or  IL-15  activated  NK  cells
o  evaluate  the  safety,  feasibility  and  clinical  activity  of  this
herapy  as  a  way  to  improve  engraftment.
To  conclude,  the  aim  of  our  study  is  to  combine  NK  cells
nd  IL-15  therapies  to  improve  the  outcome  of  umbilical
ord  blood  transplantation  by  stimulating  umbilical  cord
lood  units  with  IL-15,  with  the  aim  to  enhance  clonogenic-
ty  capacity,  homing  and  engraftment  of  umbilical  cord  blood
ematopoietic  stem  cells  and  therefore  improve  transplan-
ation  outcome  due  to  NK  cell  activation.R.  Laza-Briviesca  et  al.
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